These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32504084)

  • 1. Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.
    Crawford Parks TE; Marcellus KA; Péladeau C; Jasmin BJ; Ravel-Chapuis A
    Hum Mol Genet; 2020 Aug; 29(13):2185-2199. PubMed ID: 32504084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.
    Ravel-Chapuis A; Bélanger G; Yadava RS; Mahadevan MS; DesGroseillers L; Côté J; Jasmin BJ
    J Cell Biol; 2012 Mar; 196(6):699-712. PubMed ID: 22431750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
    Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
    PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle-specific expression of the RNA-binding protein Staufen1 induces progressive skeletal muscle atrophy via regulation of phosphatase tensin homolog.
    Crawford Parks TE; Ravel-Chapuis A; Bondy-Chorney E; Renaud JM; Côté J; Jasmin BJ
    Hum Mol Genet; 2017 May; 26(10):1821-1838. PubMed ID: 28369467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
    Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
    Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
    Neault N; Ravel-Chapuis A; Baird SD; Lunde JA; Poirier M; Staykov E; Plaza-Diaz J; Medina G; Abadía-Molina F; Jasmin BJ; MacKenzie AE
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
    Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
    Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
    Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
    J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
    Klein AF; Gasnier E; Furling D
    Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
    de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
    Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.
    Ravel-Chapuis A; Al-Rewashdy A; Bélanger G; Jasmin BJ
    Hum Mol Genet; 2018 Oct; 27(19):3361-3376. PubMed ID: 29982462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
    Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
    PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.
    Ravel-Chapuis A; Bélanger G; Côté J; Michel RN; Jasmin BJ
    Hum Mol Genet; 2017 Jun; 26(12):2192-2206. PubMed ID: 28369518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
    Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
    ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
    Morriss GR; Rajapakshe K; Huang S; Coarfa C; Cooper TA
    Hum Mol Genet; 2018 Aug; 27(16):2789-2804. PubMed ID: 29771332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.
    Charlet-B N; Savkur RS; Singh G; Philips AV; Grice EA; Cooper TA
    Mol Cell; 2002 Jul; 10(1):45-53. PubMed ID: 12150906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.
    Ravel-Chapuis A; Klein Gunnewiek A; Bélanger G; Crawford Parks TE; Côté J; Jasmin BJ
    Mol Biol Cell; 2016 Jun; 27(11):1728-39. PubMed ID: 27030674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1.
    Nakamori M; Kimura T; Kubota T; Matsumura T; Sumi H; Fujimura H; Takahashi MP; Sakoda S
    Neurology; 2008 Feb; 70(9):677-85. PubMed ID: 18299519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
    González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
    PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.